No benefit from intensive treatment

Patients were randomly assigned to either an intensive glycaemic treatment strategy to keep their HbA1c levels below 6% or a standard treatment strategy ensuring HbA1c stayed at 7–7.9%. Cognitive ability and brain volume were tested at specific time points. 

From the results, cognitive ability did not differ between the two groups, although patients in the intensive group did have significantly larger brain volume at 40 months. 

The trial was cut short in 2008 because of increased mortality in the intensive treatment group. Hypoglycaemic events and weight gain were also more common among this group.

Lancet Neurology, online 28 September